Cargando…

5′ ALK Amplification in Neuroblastoma: A Case Report

Neuroblastoma is the most common cancer in infants younger than 12 months of age, occurring with an incidence of 1 in 100,000 children. The clinical outcome of neuroblastoma ranges from spontaneous regression to treatment-resistant progression and/or metastasis, and accounts for 8–10% of childhood c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akhavanfard, Sara, Nohr, Erik, AlNajjar, Mohammad, Haughn, Mollie, Hashimoto, Sayaka, Deeg, Carol, Pfau, Ruthann, Brundler, Marie-Anne, Reshmi, Shalini C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077488/ https://www.ncbi.nlm.nih.gov/pubmed/33976638 http://dx.doi.org/10.1159/000512187

Ejemplares similares

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients
por: Alshareef, Abdulraheem, et al.
Publicado: (2018)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
por: Javanmardi, Niloufar, et al.
Publicado: (2019)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
por: Guan, J., et al.
Publicado: (2016)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Activating mutations in ALK provide a therapeutic target in neuroblastoma
por: George, Rani E., et al.
Publicado: (2008)

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT
por: Debruyne, D N, et al.
Publicado: (2016)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

Detection of tumor ALK status in neuroblastoma patients using peripheral blood
por: Combaret, Valérie, et al.
Publicado: (2015)

ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells
por: Gonzalez Malagon, Sandra G, et al.
Publicado: (2018)

ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
por: Lee, Ji Won, et al.
Publicado: (2018)

Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration
por: Huang, Hao, et al.
Publicado: (2021)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification
por: Hanna, Matthew G., et al.
Publicado: (2015)

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC
por: Zito Marino, Federica, et al.
Publicado: (2020)

The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas
por: Miyazaki, Makoto, et al.
Publicado: (2018)

ALK gene amplification is associated with poor prognosis in colorectal carcinoma
por: Bavi, P, et al.
Publicado: (2013)

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma
por: Hasan, Md. Kamrul, et al.
Publicado: (2013)

NeuroD1 promotes neuroblastoma cell growth by inducing the expression of ALK
por: Lu, Fangjin, et al.
Publicado: (2015)

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
por: Guan, Jikui, et al.
Publicado: (2017)

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
por: Cervantes-Madrid, Diana, et al.
Publicado: (2019)

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
por: Wulf, Anna M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_664n7cqodmlhj02snj7lvopos6